These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17514769)

  • 1. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
    Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
    Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
    Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
    BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
    Trudel S; Trachtenberg J; Toi A; Sweet J; Li ZH; Jewett M; Tshilias J; Zhuang LH; Hitt M; Wan Y; Gauldie J; Graham FL; Dancey J; Stewart AK
    Cancer Gene Ther; 2003 Oct; 10(10):755-63. PubMed ID: 14502228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
    Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
    Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
    Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
    Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
    Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
    J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.
    Brill TH; Kübler HR; Pohla H; Buchner A; Fend F; Schuster T; van Randenborgh H; Paul R; Kummer T; Plank C; Eisele B; Breul J; Hartung R; Schendel DJ; Gansbacher B
    Hum Gene Ther; 2009 Dec; 20(12):1641-51. PubMed ID: 19671000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
    Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
    Noguchi M; Itoh K; Yao A; Mine T; Yamada A; Obata Y; Furuta M; Harada M; Suekane S; Matsuoka K
    Prostate; 2005 Apr; 63(1):1-12. PubMed ID: 15378520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
    van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
    Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
    Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.